PMID: 6968766Nov 1, 1980Paper

Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity

The Journal of Immunology : Official Journal of the American Association of Immunologists
G B MillsV Paetkau

Abstract

Spleen cells from DBA/2J mice bearing the syngeneic tumor mastocytoma P815, incubated with co-stimulator (Interleukin 2) and P815 in vitro, were effective in killing P815 cells in vivo. Within 24 hr of injection, 1 X 10(7) cytotoxic lymphocytes (CL) killed most of 1 X 10(6) P815 cells. The host response to the tumor 7 to 9 days after the initial tumor injection was also greatly enhanced in mice that had received CL. This effect was potentiated in sublethally irradiated mice. CL were effective in mice with large tumors, overcoming suppressive factors that might be present. Under certain conditions, a significant fraction of CL-treated mice survived the P815 tumor indefinitely. These included i.p. CL given 2 days after a large dose (1 X 10(6)) of i.p. P815. In addition, some mice given i.v. and intra-tumor CL survived small doses (1 X 10(4)) of subcutaneous P815 cells. Long-term surviving mice remained resistant to challenge with 1 X 10(6) tumor cells (which is 10(4) times the normally lethal dose) for at lest 1 yr. No detrimental effects were noted even after injection of 5 X 10(7) CL per mouse.

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

© 2021 Meta ULC. All rights reserved